(Q38171862)

30 August 2017

title

The use of fecal calprotectin as a biomarker in gastrointestinal disease (English)

1 reference

30 August 2017

0 references

0 references

Emanuel Burri

1

1 reference

30 August 2017

Christoph Beglinger

series ordinal

2

1 reference

30 August 2017

publication date

18 December 2013

1 reference

Expert Review of Gastroenterology & Hepatology

30 August 2017

published in

1 reference

30 August 2017

volume

8

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

197-210

1 reference

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

ANTI-INFECTIVE PROTECTIVE PROPERTIES OF S100 CALGRANULINS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Mucosal healing in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Mucosal healing in inflammatory bowel diseases: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Faecal calprotectin in children with clinically quiescent inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Evaluation of faecal calprotectin as a valuable non-invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Prophylactic aspirin therapy does not increase faecal calprotectin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Review article: the current and evolving treatment of colonic diverticular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Faecal calprotectin in colonic diverticular disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Biomarkers in diverticular diseases of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Can chronic gastritis cause an increase in fecal calprotectin concentrations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue')

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Calprotectin: a novel noninvasive marker for intestinal allograft monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin level measurements in small bowel allograft monitoring: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Rapid fecal calprotectin correlates with clinical and endoscopic severity of inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Diagnostic Accuracy of Point-of-Care Fecal Calprotectin and Immunochemical Occult Blood Tests for Diagnosis of Organic Bowel Disease in Primary Care: The Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

A combination of faecal tests for the detection of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.869476

10.1586/17474124.2014.869476

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference